Canine Arthritis Treatment Market Size and Trends
The global canine arthritis treatment market was valued at US$ 2.42 billion in 2023. The demand for canine arthritis treatment medications is expected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching a market valuation of US$ 3.73 billion by 2032.
The global canine arthritis treatment market is experiencing significant growth, driven by rising pet ownership and increasing awareness of pet health. Canine arthritis, a common condition in aging dogs, affects joints and mobility, leading to pain and reduced quality of life. Owners are becoming more proactive in seeking treatments, including pharmaceuticals, dietary supplements, and physical therapies, to improve their pets’ well-being.
Pharmaceutical treatments, particularly non-steroidal anti-inflammatory drugs (NSAIDs), dominate the market due to their efficacy in managing pain and inflammation. However, there is a growing demand for alternative and complementary therapies, such as nutraceuticals, which include glucosamine and chondroitin supplements. These options are preferred by pet owners looking for natural, less invasive treatments.
Technological advancements are also shaping the market. Innovations in veterinary medicine, such as regenerative therapies (stem cell therapy and platelet-rich plasma), are gaining traction for their potential to repair and regenerate damaged tissues. Additionally, the development of new drug formulations and delivery methods, such as long-acting injections and transdermal patches, offer more convenient and effective treatment options.
The market is highly competitive, with key players focusing on expanding their product portfolios and geographic reach. Increased investment in research and development, along with strategic collaborations and partnerships, are expected to drive further growth in the canine arthritis treatment market in the coming years.
Competitive Landscape
Major companies and manufacturers in the canine arthritis treatment market, including Boehringer Ingelheim International GmbH, DAIICHI SANKYO COMPANY, LIMITED, Thorne, NUTRI-VET, American Regent, Inc., and DSM, are heavily investing in research and development to innovate new medications, supplements, and therapeutic approaches. These companies are also expanding their distribution networks and forming partnerships with veterinary clinics, pet retailers, and online platforms to enhance the market reach and accessibility of their products to pet owners.
Category-wise Insights
Pet Owners are Increasingly Preferring NSAIDs for Canine Arthritis Treatments
The NSAIDs category is projected to hold the largest share of the canine arthritis treatment market in 2024, accounting for 72% of the global market. The demand for NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) has skyrocketed in recent decades due to their high effectiveness in relieving pain and inflammation associated with canine arthritis. Veterinary professionals frequently prescribe NSAIDs due to their proven effectiveness and safety profile in managing arthritis symptoms in dogs, making them the most sought-after treatment option for pet owners.
Attributes
- Drug Class: NSAIDs
- Market Share: 72.00%
Veterinary Professionals are Prescribing Oral Treatments for Canine Arthritis
The market is also segmented by route of administration into oral and injectable treatments, with the oral segment dominating at 70% market share in 2024. Both pet owners and veterinary professionals are increasingly choosing oral treatments for their convenience in administration. Oral treatments offer easy integration into a dog’s daily routine and provide flexibility in dosing and administration schedules. This minimizes the risk of complications associated with injectable therapies, such as injection site reactions.
Attributes
- Route of Administration: Oral
- Market Share: 70.00%
Recent Developments
TVM’s DogStem Therapy (January 2023): TVM introduced DogStem, Europe’s first licensed stem cell therapy for canine osteoarthritis. Clinical trials have shown its efficacy in improving gait and orthopedic examination results. Pet owners reported enhanced mobility and quality of life for their dogs, with effects lasting up to eighteen months.
Elanco’s Galliprant Launch (May 2019): Elanco launched Galliprant, a new treatment for canine osteoarthritis pain, in the UK. Galliprant targets the EP4 receptor, reducing pain and inflammation without affecting gastrointestinal and kidney functions. It offers a promising solution for managing osteoarthritis discomfort in dogs.
Rejuvenate Bio’s Gene Therapy Partnership (February 2024): Rejuvenate Bio partnered with a leading animal health company to develop and commercialize groundbreaking gene therapy for canine osteoarthritis. This therapy aims to address the condition’s widespread prevalence and severe consequences, potentially revolutionizing dog health.
Key Companies in the Market
- Boehringer Ingelheim International GmbH
- DAIICHI SANKYO COMPANY, LIMITED
- Thorne
- NUTRI-VET
- American Regent, Inc.
- DSM
- Zoetis
- National Hog Farmer
- Novasep
- Bayer AG
- Matsun Nutrition
Canine arthritis treatment Market by Segmentation
By Treatment:
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Opioids
- Stem Cell Therapy
- Allogeneic Stem Cells
- Autologous Stem Cells
By Route of Administration:
- Oral Canine Arthritis Treatment
- Injectable Canine Arthritis Treatment
By Distribution Channel:
- Veterinary Hospitals & Clinics
- Retail Pharmacies
- Drug Stores
- e-Commerce
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa (MEA)
- Europe
Table of Content
Chapter 1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
Chapter 2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
Chapter 3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
Chapter 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
Chapter 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2024 to 2032
5.3.1. Non-steroidal anti-inflammatory Drugs (NSAIDs)
5.3.2. Opioids
5.3.3. Stem Cell Therapy
5.3.4. Allogeneic Stem Cells
5.3.5. Autologous Stem Cells
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Treatment, 2024 to 2032
Chapter 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2024 to 2032
6.3.1. Oral
6.3.2. Injectable
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2032
Chapter 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2032
7.3.1. Veterinary Hospitals & Clinics
7.3.2. Retail Pharmacies
7.3.3. Drug Stores
7.3.4. E-Commerce
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2032
Chapter 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
Chapter 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2032
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Treatment
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
Chapter 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
Chapter 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Treatment
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
Chapter 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2032
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Treatment
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
Chapter 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Treatment
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
Chapter 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2032
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Treatment
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
Chapter 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2032, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2032
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Treatment
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Treatment
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
Chapter 16. Key Countries Market Analysis
16.1. USA
16.1.1. Market Share Analysis, 2023
16.1.1.1. By Treatment
16.1.1.2. By Route of Administration
16.1.1.3. By Distribution Channel
16.2. Canada
16.3. Brazil
16.4. Mexico
16.5. Germany
16.6. UK
16.7. France
16.8. Spain
16.9. Italy
16.10. Poland
16.11. Russia
16.12. Czech Republic
16.13. Romania
16.14. India
16.15. Bangladesh
16.16. Australia
16.17. New Zealand
16.18. China
16.19. Japan
16.20. South Korea
16.21. GCC Countries
16.22. South Africa
16.23. Israel
Chapter 17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Treatment
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
Chapter 18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Boehringer Ingelheim International GmbH.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. DAIICHI SANKYO COMPANY, LIMITED
18.1.3. Thorne
18.1.4. Nutri-Vet
18.1.5. American Regent, Inc.
18.1.6. DSM
18.1.7. Zoetis
18.1.8. National Hog Farmer
18.1.9. Novasep
18.1.10. Bayer AG
18.1.11. Matsun Nutrition
Chapter 19. Assumptions & Acronyms Used
Chapter 20. Research Methodology
